Evidence map›Paper›PMID 40958074›Full record

ArticleFolia microbiologica2025

Effect of riboflavin and roseoflavin, a structural analogue of riboflavin, on the growth of selected microbial isolates from human saliva using a riboflavin-free cultivation medium.

Nadja Schwendenmann, Sophie Burger, Leonie Steiner, Lars Seufert, Matthias Kohl, Matthias Mack, Markus Egert

Abstract read
PubMed Publisher
In one paragraph

Article in Folia microbiologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nadja SchwendenmannFaculty of Health, Medical and Life Sciences, Microbiology and Hygiene Group, Institute of Precision Medicine, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany.ORCID http://orcid.org/0009-0002-6907-2902
Sophie BurgerFaculty of Health, Medical and Life Sciences, Microbiology and Hygiene Group, Institute of Precision Medicine, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany.ORCID http://orcid.org/0009-0001-8861-0959
Leonie SteinerFaculty of Health, Medical and Life Sciences, Microbiology and Hygiene Group, Institute of Precision Medicine, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany.
Lars SeufertInstitute of Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany.
Matthias KohlFaculty of Health, Medical and Life Sciences, Bioinformatics and Biostatistics Group, Institute of Precision Medicine, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany.ORCID http://orcid.org/0000-0001-9514-8910
Matthias MackInstitute of Technical Microbiology, Mannheim University of Applied Sciences, Mannheim, Germany.ORCID http://orcid.org/0000-0002-7753-2422
Markus EgertFaculty of Health, Medical and Life Sciences, Microbiology and Hygiene Group, Institute of Precision Medicine, Furtwangen University of Applied Sciences, Villingen-Schwenningen, Germany. Markus.Egert@hs-furtwangen.de.ORCID http://orcid.org/0000-0003-2402-3322

Funding

Baden-Württemberg Stiftung Microbiome Programme
6 · The paper itself

Abstract

The antivitamin roseoflavin (RoF) is a structural analogue and competitive inhibitor of riboflavin (RF, vitamin B

Indexed as

AntivitaminOral microbiotaRiboflavinRoseoflavinStreptococcus

Identifiers

PMID40958074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.